Advertisement

Antipsychotic gets nod for second indication

Janssen has received word from the FDA giving it the green light to market Invega for long-term maintenance treatment of schizophrenia.

Antipsychotic gets nod for second indicationJanssen has received word from the FDA giving it the green light to market Invega for long-term maintenance treatment of schizophrenia. The atypical antipsychotic drug was previously approved in December 2006 for acute (short-term) treatment of the illness. The drug provided a significant benefit in delaying the time to relapse of symptoms of schizophrenia in a long-term efficacy study on which the FDA based its approval. The once-daily extended-release tablets contain paliperidone, the active metabolite of risperidone.

To see more Hot off the Press news articles, click here.

Advertisement

To go to the Drug Topics homepage, click here.


Advertisement
Advertisement